China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+86-898-66811730
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees276
Next Earnings Date4/2/2019 (Estimated)
OptionableNot Optionable
China Pharma (NYSEAMERICAN:CPHI) Frequently Asked Questions
What is China Pharma's stock symbol?
China Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CPHI."
How were China Pharma's earnings last quarter?
China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) posted its quarterly earnings data on Wednesday, August, 15th. The company reported ($0.02) earnings per share for the quarter. The business earned $3.17 million during the quarter. View China Pharma's Earnings History.
When is China Pharma's next earnings date?
Has China Pharma been receiving favorable news coverage?
News coverage about CPHI stock has trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. China Pharma earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
Are investors shorting China Pharma?
China Pharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totalling 55,193 shares, a decrease of 54.7% from the December 31st total of 121,920 shares. Based on an average trading volume of 365,289 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the shares of the company are sold short. View China Pharma's Current Options Chain.
Who are some of China Pharma's key competitors?
Some companies that are related to China Pharma include NanoViricides (NNVC), Patrys (PAB), Avivagen (VIV), Recce Pharmaceuticals (RCE), Antisense Therapeutics (ANP), Allergy Therapeutics (AGY), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), Hutchison China MediTech (HCM) and N4 Pharma (N4P).
What other stocks do shareholders of China Pharma own?
Who are China Pharma's key executives?
China Pharma's management team includes the folowing people:
- Ms. Zhilin Li, Pres, CEO, Chairman & Interim CFO (Age 66)
- Ms. Yao Huang, Chief Technical Officer
- Ms. Jian Yang, Sec. (Age 59)
Who are China Pharma's major shareholders?
China Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.22%).
Which major investors are buying China Pharma stock?
CPHI stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
How do I buy shares of China Pharma?
Shares of CPHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Pharma's stock price today?
One share of CPHI stock can currently be purchased for approximately $0.2679.
How big of a company is China Pharma?
China Pharma has a market capitalization of $11.68 million. China Pharma employs 276 workers across the globe.
What is China Pharma's official website?
How can I contact China Pharma?
China Pharma's mailing address is 2Nd Floor, No. 17, Jinpan Road, Haikou, HAIKOU, HAN 570216, China. The company can be reached via phone at +86-898-66811730.
MarketBeat Community Rating for China Pharma (NYSEAMERICAN CPHI)
MarketBeat's community ratings are surveys of what our community members think about China Pharma and other stocks. Vote "Outperform" if you believe CPHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
